How does FOXO4-DRI work?
Dominant-negative interfering peptide that disrupts the FOXO4-p53 interaction. In senescent cells, FOXO4 normally protects against p53-driven apoptosis; blocking the interaction selectively triggers death of senescent ('zombie') cells. In plain terms, FOXO4-DRI is fOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Researchers studying senolytics
- Longevity-research contexts under medical guidance
- Educational reference, limited human safety data
References
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging — Baar MP et al., Cell, 2017
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline — Alameen AAM et al., Naunyn-Schmiedeberg's Arch Pharmacol, 2026
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — Kong YX et al., Communications Biology, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on FOXO4-DRI
Last updated 2026-06-06.